+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease



Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease



Journal of Pediatric Gastroenterology and Nutrition 54(5): 685-689



We hypothesised that nonadherence to thiopurines is more common in adolescents than in adults with inflammatory bowel disease. We sought factors associated with thiopurine nonadherence defined by thiopurine metabolite levels. Multivariate logistic regression confirmed that adolescents (odds ratio [OR] 4.6 [95% confidence interval [CI] 1.9-11.5]; P < 0.01) compared with adults, patients with Crohn disease (OR 3.3 [CI 1.1-10.5] P = 0.04) compared with ulcerative colitis, and patients living in more socially deprived areas (OR 1.03 [CI 1.0-1.1] P = 0.02) were more likely to be nonadherent to thiopurines. Adolescents are more frequently nonadherent than adults: prospective studies are required to determine the reasons for nonadherence in adolescents.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053193809

Download citation: RISBibTeXText

PMID: 22197942

DOI: 10.1097/mpg.0b013e3182475e71


Related references

Lymphoma: the bête noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 145(5): 927-930, 2013

Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Digestive and Liver Disease 49(4): 405-411, 2017

Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflammatory Bowel Diseases 17(6): 1270-1276, 2011

How I treat my inflammatory bowel disease-patients with thiopurines?. World Journal of Gastrointestinal Pharmacology and Therapeutics 7(4): 524-530, 2016

Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology 9(7): 891-900, 2015

Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflammatory Bowel Diseases 19(10): 2199-2206, 2013

Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease. Journal of Crohn's and Colitis 3(3): 196-199, 2009

Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflammatory Bowel Diseases 18(2): 261-268, 2012

How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?. Scandinavian Journal of Gastroenterology 46(10): 1215-1221, 2011

Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 61(2): 235-240, 2012

Transitioning patients with inflammatory bowel disease (IBD) from adolescent to adult services: a systematic review. Frontline Gastroenterology 7(4): 264-270, 2016

Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?. Expert Review of Clinical Immunology 10(12): 1563-1565, 2014

Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clinical Gastroenterology and Hepatology 12(11): 1793-1800.E1, 2014

Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. Journal of Clinical Pharmacy and Therapeutics 35(1): 93-97, 2010

Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 39(6): 584-588, 2017